Breaking AI & Tech News Analyzed

Lawyers estimate that as many as 75 women could have a claim in the $72.5 million settlement reached with Bank of America over alleged involvement in Jeffrey Epstein’s sex‑trafficking network. U.S. District Judge Jed Rakoff has instructed counsel to assemble a broad list of publications by the upcoming Friday to ensure every potential victim receives notice, emphasizing that "nobody is left out." A final approval hearing is scheduled for August 27. The settlement was first disclosed in court filings on March 27 after a proposed class‑action lawsuit was permitted to move forward. In October, a plaintiff using the pseudonym Jane Doe filed the suit on behalf of herself and other alleged victims, accusing the bank of overlooking suspicious transactions tied to Epstein’s operations. According to the complaint, Bank of America allegedly benefited knowingly from its relationship with Epstein and impeded enforcement of the Trafficking Victims Protection Act, a federal statute aimed at combating sex trafficking. Bank of America reiterated its stance that it did not facilitate Epstein’s crimes, stating that the resolution allows the institution to move past the matter and provides "further closure for the plaintiffs." Judge Rakoff gave preliminary approval, noting that while no monetary figure can fully compensate for the magnitude of Epstein’s offenses, victims are entitled to restitution from any party that "knowingly, recklessly or otherwise unlawfully facilitated" the trafficking. This agreement follows similar settlements in 2023: JPMorgan Chase paid $290 million and Deutsche Bank settled for $75 million with Epstein victims. Rakoff previously dismissed a suit against Bank of New York Mellon; the plaintiffs are now appealing that decision. He stressed that liability should be limited to entities that knowingly assisted or profited, not to every organization that merely intersected with Epstein’s network. Jeffrey Epstein, a wealthy financier who died by suicide in a New York City jail in 2019, was accused of preying on girls and young women for decades and maintained ties to high‑profile figures across politics, arts, and business. One of Doe’s attorneys, David Boies, believes that 60 to 75 women may qualify for the settlement, and cautions that additional claimants could emerge as the search continues.

The World Health Organisation (WHO) has issued a stern warning against the ongoing US-Israeli attacks on Iranian healthcare facilities, amid the escalating conflict. The organisation's chief, Tedros Adhanom Ghebreyesus, reported that over 20 attacks on healthcare facilities in Iran have been verified since March 1, resulting in at least nine deaths, including an infectious diseases health worker and a member of the Iranian Red Crescent Society.The Pasteur Institute in Tehran, one of the oldest research and health facilities in the country, has sustained significant damage and was rendered unable to continue delivering health services. Iranian Ministry of Health spokesperson Hossein Kermanpour shared images of the heavily damaged building on social media, with parts of the facility reduced to rubble.Despite the attacks, Iran's ISNA news agency reported that the services of the Pasteur Institute have not been interrupted, and vaccine and serum production would continue. The WHO chief emphasised that the Institute plays a crucial role in protecting and promoting population health, particularly in emergencies.The attacks have not been limited to the Pasteur Institute. The WHO has reported damage to other healthcare facilities, including the Delaram Sina Psychiatric Hospital and the Tofigh Daru pharmaceutical facility, with no casualties reported. An explosion near the Imam Ali Hospital in Khuzestan province led to the facility's evacuation and cessation of services.Tedros stressed that humanitarian workers, ambulances, relief supplies, and humanitarian facilities must be respected and protected under international law. The Geneva Conventions, agreed upon after World War II, designate healthcare facilities as protected locations.The Iranian Red Crescent Society reported that a warehouse belonging to the organisation was targeted, destroying two-wheeled relief containers and two buses and relief vehicles. According to the organisation, 307 health, medical, and emergency care facilities have been damaged in the war.

Approximately two dozen Democratic‑led states and the District of Columbia have lodged a federal lawsuit against President Donald Trump to block a newly issued executive order that would sharply limit mail‑in and absentee voting. The filing, submitted on Friday, comes as voting‑rights groups warn the measure is designed to make voting harder ahead of the 2026 midterm elections, which will decide control of both chambers of Congress. New York Attorney General Letitia James, representing 23 states and D.C., said the order "exceeds the president’s constitutional authority" and undermines the principle that states set the times, places and manner of elections. "Free and fair elections are the cornerstone of our democracy, and no president has the power to rewrite the rules on his own," James stated. The contested order, signed on Tuesday, directs the Department of Homeland Security to compile a nationwide list of eligible voters and instructs the United States Postal Service to deliver ballots only to individuals on a "State‑specific Mail‑in and Absentee Participation List." Critics argue the list would be incomplete and would place an undue burden on the USPS. Voting‑rights advocates note that mail‑in voting surged after the COVID‑19 pandemic, with one‑third of all 2024 ballots cast by mail, a trend that cuts across both Republican and Democratic states. In their complaint, the states contend that only Congress, not the president, may impose new restrictions on election administration, and that implementing such changes so close to the November vote would generate significant logistical chaos. President Trump maintains the action is needed to combat "rampant voter fraud," a claim repeatedly debunked by independent monitors, including the Heritage Foundation, which reports fraud rates are exceedingly low. Beyond the lawsuit, the Justice Department has pursued separate legal actions to obtain voter data, and the FBI’s recent raid on a Georgia election office has heightened concerns about election integrity. Trump is also urging Congress to pass the "SAVE America Act", which would require proof of U.S. citizenship—such as a birth certificate or passport—and a photo ID for ballot casting. Rights groups warn the proposal could disenfranchise many voters, including women who have changed their surnames after marriage.

In the face of a downbeat hospitality trend in the UK, food halls are emerging as a beacon of hope, offering a diverse culinary experience that is proving resilient to economic challenges. The Cambridge Street Collective in Sheffield, Europe's largest purpose-built food hall at 20,000 sq ft, exemplifies this trend. Opened in 2024, it features a variety of vendors offering everything from sushi tacos to Palestinian cuisine.The food hall sector is experiencing significant growth, with major UK cities averaging £5.6m in annual revenue and a year-on-year growth rate of 10.75%. This growth is attributed to the shared infrastructure and risk model, where vendors pay a cut of their sales each month, and the owner covers costs such as energy and staffing. This model allows for a lower-risk entry point for entrepreneurs and innovative food concepts.65 new food halls are currently in development across the UK, including a 60,000 sq ft venue in Newcastle and a growing scene in cities like Manchester, Liverpool, and London. These food halls are not just about food; they offer a community space where people can work, socialize, and enjoy a variety of cuisines.Matt Farrell, founder of Bold Street Coffee, notes that food halls have become incubators for new businesses, providing opportunities for operators who can't afford traditional sites. James Cowan of Blend Collective, the owner of Cambridge Street Collective, emphasizes the importance of hosting local businesses and keeping the offering fresh.Successful food hall vendors have gone on to open their own brick-and-mortar restaurants, such as Baity, a Palestinian chain with sites in multiple cities, and Bao, which started in London's Netil Market. These success stories highlight the potential for food halls to foster culinary innovation and entrepreneurship.While some may wonder if the UK has reached peak food hall, industry experts believe there is still room for growth, particularly in areas with high demand and limited offerings. As the economic climate continues to evolve, food halls are likely to remain a vibrant part of the UK's culinary landscape.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

Even before the season began, the fixture list hinted that March would become a turning point for Newcastle United. A run to the Champions League quarter‑finals and a victory in the Tyne‑Wear derby could have silenced many critics, while a third Carabao Cup final would have forced the derby’s postponement. In the Champions League round‑of‑16, Newcastle appeared stronger at home against Barcelona, only to be undone by a late penalty. The away leg saw them threaten early on, but a second‑half collapse resulted in a 7‑2 defeat, widening the perceived gap between the sides. The derby itself illustrated the team’s frailties. Newcastle led at halftime and struck the post, yet they finished with the fifth‑worst second‑half record in the Premier League. Sunderland equalised through Brian Brobbey, fed by a simple Granit Xhaka pass, exploiting the space that Newcastle’s midfield surrendered late in the game. These setbacks have sparked serious speculation about manager Eddie Howe’s future. Chief executive David Hopkinson offered no clear endorsement, stating only that “we’ll talk about the future when it’s time,” a comment that many interpreted as a warning. Howe arrived in November 2021, a month after the Saudi‑led acquisition of the club, and quickly guided Newcastle into the modern era: two Champions League qualifications, a historic Carabao Cup triumph – the first domestic trophy in 70 years – and a generally steady league performance. Until last season, there was little talk of his dismissal. However, the current crisis is less about tactics than about recruitment. With no sporting director, Howe’s nephew Andy Howe and scout Steve Nickson oversaw most signings last summer, a structure that has drawn criticism. The sale of Alexander Isak to Liverpool was widely regarded as mishandled. The club allowed the protracted saga to dominate the window, missing an opportunity to maximise the fee and reinvest in squad depth, or to negotiate a swap that could have brought Hugo Ekitiké to Newcastle. Summer acquisitions have added little stability. While Sandro Tonali, Anthony Gordon and Tino Livramento are rumored to be on their way out, Yoane Wissa suffered an early injury and new signing Nick Woltemade arrived without a clear role. Of the incoming players, only Malick Thiaw has made a noticeable impact. Consequently, the squad lacks the depth required for simultaneous Champions League commitments, a Carabao Cup semi‑final run, and a fifth‑round FA Cup tie. The fatigue evident in many second‑half performances is therefore unsurprising. Underlying these on‑field issues are broader structural problems. Dan Ashworth’s departure for Manchester United left a void that successor Paul Mitchell could not fill; his exit after clashes with ownership – and reportedly with Howe over player conditioning – created a leadership vacuum. Ross Wilson, appointed sporting director in October with Howe’s blessing, now faces the daunting task of rebuilding a fragmented recruitment process. Financial pressures add another layer of complexity. The recent sale of the stadium to a club subsidiary, coupled with a looming UEFA fine for 2025, has strained resources. While the Champions League revenue and the Isak transfer may alleviate some of the strain, the shift to an “unanchored” squad‑cost ratio favours owners with deep pockets, leaving the club’s commitment from the Public Investment Fund uncertain amid broader Saudi retrenchment. Notably, discussions of a new stadium have been absent for almost a year. Hopkinson’s description of Newcastle as a “trading club” appears realistic, yet his remarks also hint at an upcoming exodus of players such as Tonali, Gordon and Livramento. Even if the broader economic climate softens, the likely absence of Champions League football next season could further limit Newcastle’s ability to attract top talent. Ultimately, the core issue is governance. While Howe’s tactical acumen may improve without the demands of European competition, the club’s ambition to become a modern, well‑structured organisation may require a change in leadership. His departure could be the catalyst needed for a comprehensive cultural and structural overhaul.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

A devastating incident unfolded at the Alejandro Villanueva Stadium in Lima, Peru, on Friday, claiming the life of one person and injuring dozens more. The event, which was a 'flag-waving' gathering, took place a day before a highly anticipated derby match between Alianza Lima and Universitario de Deportes.The Peruvian health minister, Juan Carlos Velasco Guerrero, confirmed the death and reported that 47 people were injured, with three in critical condition. Initial reports suggested that parts of the stadium's wall had collapsed, but officials later clarified that there were no structural failures.Alianza Lima expressed condolences for the casualties and pledged to cooperate fully with authorities to investigate the incident. The club promised 'total transparency' in the investigation.The Peruvian professional soccer league announced that Saturday's match would proceed as planned, emphasizing its commitment to ensuring safe environments for spectators. The league will continue to work closely with clubs and authorities to promote safety and wellbeing at sporting events.The Alejandro Villanueva Stadium, also known as Matute, was built in the 1970s and has a capacity of over 33,900 seats. Despite limited modernization, the stadium remains a 'fairly basic ground,' according to The Stadium Guide.

South Carolina defeated UConn 62‑48 in the women’s NCAA Final Four on Friday night, snapping the Huskies’ 54‑game winning streak and booking the Gamecocks a spot in the national championship.With just 0.1 seconds left on the clock, the two veteran coaches met at the scorer’s table. Geno Auriemma raised his voice toward Dawn Staley, prompting a sharp retort from the South Carolina coach. Assistant coaches intervened before UConn could inbound the final play.In the post‑game press conference, Staley emphasized her integrity, saying she had shaken hands with every member of Auriemma’s staff before the game and was unaware of any perceived slight. "Sometimes things get heated, we move on," she told ESPN’s Holly Rowe.Auriemma, who later described the exchange as “nothing,” reiterated that he simply said what he felt was necessary, while Staley deflected responsibility, noting that he had initiated the conversation.Earlier in the fourth quarter, Auriemma vented frustration over officiating, alleging a series of fouls called against his team and accusing the opposing coach of “rants and raves” that distracted from the game.The loss exposed offensive struggles for UConn’s All‑America duo. Sarah Strong, the national player of the year, managed only 12 points on 4‑of‑16 shooting, and Azzi Fudd contributed eight points on 3‑of‑15, including a poor three‑point performance (2‑of‑9). In contrast, South Carolina’s Ta’Niya Latson scored 16 points and Agot Makeer added 14.Defensively, the game was a battle: UConn was called for 17 fouls, while South Carolina drew just eight. The Gamecocks’ interior size limited Strong’s attempts, and the Huskies could not find rhythm, recording their lowest point total since a 49‑point effort in the 2022 championship loss.UConn entered the Final Four with a 38‑1 record, marking their ninth undefeated run to the semifinal and the third consecutive year they fell short of the title. South Carolina (34‑3) will now face UCLA for a chance at their fourth national championship.